<DOC>
	<DOCNO>NCT02702011</DOCNO>
	<brief_summary>To assess safety , tolerability , pharmacokinetics , pharmacodynamics daily oral dos empagliflozin Japanese patient type 1 diabetes mellitus adjunctive therapy insulin .</brief_summary>
	<brief_title>Empa Add Insulin Japanese Patient With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Signed date write informed consent date Visit 1 ( screen ) accordance Good Clinical Practice ( GCP ) local legislation Japanese male female patient receive insulin treatment document diagnosis type 1 diabetes mellitus ( T1DM ) least 1 year time Visit 1 ( screen ) . Fasting Cpeptide value &lt; 0.6 ng/mL Visit 2 ( placebo runin ) measure central laboratory Use , willing , base investigator 's judgment , continue throughout duration trial Multiple daily injection ( MDI ) insulin consist least 1 basal insulin injection least 3 daily bolus injection The total daily insulin dose must &gt; =0.3 U/kg &lt; =1.5 U/kg Visit 1 ( screen ) HbA1c 7.5 % 10.0 % Visit 1 ( screen ) measure central laboratory provide patient HbA1c increase &gt; 0.5 % within 3 month Visit 1 ( screen ) Based investigator 's judgment , patient must good understand his/her disease manage , willing capable perform follow study assessment ( assessed Visits 1 3 randomization ) patientled management adjustment insulin therapy reliable approach insulin dose adjustment meal , carbohydrate counting reliable regular homebased blood glucose monitor recognize symptom DKA , reliably monitor ketone implementation establish `` sick day '' management regimen Age &gt; =20 year &lt; =65 year Visit 1 ( screen ) Body mass index ( BMI ) &gt; =18.5 kg/m2 &lt; =35.0 kg/m2 Visit 1 ( screen ) Estimated glomerular filtration rate ( eGFR ) &gt; =60 mL/min/1.73m² &lt; =150 mL/min/1.73m² calculate Japanese equation base creatinine measure central laboratory Visit 1 ( screen ) Compliance trial drug administration must 80 % 120 % placebo runin period , judge Visit 4 randomization Exclusion criterion : History T2DM , maturity onset diabetes young ( MODY ) , pancreatic surgery chronic pancreatitis Pancreas , pancreatic islet cell renal transplant recipient T1DM treatment antihyperglycaemic drug ( e.g. , metformin , alphaglycosidase inhibitor , glucagonlikepeptide 1 ( GLP1 ) receptor agonist , SGLT2 inhibitor , pramlintide , inhaled insulin , premixed insulin , etc . ) within 3 month except subcutaneous basal bolus insulin Visit 1 ( screen ) history clinically relevant hypersensitivity accord investigator 's judgment Occurrence severe hypoglycemia involve coma and/or seizure require hospitalization hypoglycemiarelated treatment emergency physician paramedic within 3 month Visit 1 ( screen ) Occurrence DKA within 3 month Visit 1 ( screen ) randomization Visit 4 ( Day 1 ) Irregular sleep/wake cycle ( e.g. , patient habitually sleep day work night ) base investigator 's judgment Acute coronary syndrome ( nonSTEMI , STEMI , unstable angina pectoris ) , stroke transient ischemic attack within 3 month Visit 1 ( screen ) Diagnosis severe gastro paresis base investigator 's judgment Diagnosis brittle diabetes base investigator 's judgment Indication liver impairment , define serum level either alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase 3 x upper limit normal ( ULN ) Visit 1 ( screen ) measure central laboratory Eating disorder bulimia anorexia nervosa Treatment antiobesity drug ( e.g. , Mazindol ) , surgery aggressive diet regimen lead unstable body weight ( base investigator 's judgment ) 3 month Visit 1 ( screen ) randomization Treatment systemic corticosteroid plan initiation therapy Visit 1 ( screen ) . Inhaled use corticosteroid ( e.g. , asthma/chronic obstructive pulmonary disease ) acceptable Change dose thyroid hormone within 6 week Visit 1 ( screen ) plan change initiation therapy Visit 1 ( screen ) Medical history cancer treatment cancer last 5 year Visit 1 ( screen ) . Resected basal cell carcinoma consider cure exempted Blood dyscrasia disorder cause hemolysis unstable red blood cell ( e.g. , malaria , babesiosis , hemolytic anemia ) Visit 1 ( screen ) Premenopausal woman ( last menstruation &lt; =1 year inform consent ) : nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , intra uterine devices/systems , oral contraceptive , complete sexual abstinence , double barrier method vasectomize partner Alcohol drug abuse within 3 month Visit 1 ( screen ) would interfere trial participation base investigator 's judgment Intake investigational drug another trial within 30 day Visit 1 ( screen ) Patient able understand comply study requirement base investigator 's judgment Any clinical condition , base investigator 's judgment , would jeopardise patient safety would affect study outcome ( e.g . immunocompromised patient might high risk develop genital mycotic infection , patient chronic viral infection , etc . ) trial participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>